Exemption of oral medicines from bioequivalence studies | New regulations
The Saudi Food and Drug Authority (SFDA) has announced a new draft regulation aimed at exempting certain oral medications from bioequivalence studies . This strategic step aims to facilitate drug evaluation while fully ensuring efficacy and safety for patients. The decision reflects the SFDA's commitment to keeping pace with the latest scientific practices in the field of pharmacy.
Evolution of global standards for drug evaluation
Historically, the approval process for generic (alternative) drugs required lengthy clinical trials in humans to demonstrate their conformity to the original, innovative reference drugs. With advancements in pharmaceutical science, the Biopharmaceutical Classification System (BCS) emerged as a globally recognized standard. This system revolutionized the pharmaceutical industry by providing a reliable alternative based on the drug's physical and chemical properties, such as solubility and permeability, rather than costly and time-consuming human trials. Many global health authorities have adopted this approach to reduce the burden on volunteers and expedite access to safe medicines for patients.
Conditions for exempting oral medicines from bioequivalence studies
The agency explained that the evidence, based on the biopharmaceutical classification system, reduces the need for clinical bioequivalence studies by relying on precise laboratory data to justify this exception. The draft revealed that the exceptions are limited exclusively to solid oral pharmaceutical products and immediate-release suspensions designed for systemic administration.
The regulatory guide explained that the adopted classification system divides pharmaceutical substances into four main categories based on their water solubility and intestinal permeability characteristics. Exemptions primarily apply to drugs containing active ingredients belonging to categories one (high solubility and permeability) and three (high solubility and low permeability). The authority emphasized that obtaining this exemption requires the active ingredient of the drug being tested to be identical to that of the reference drug, with the inactive ingredients also being perfectly compatible.
Strict restrictions on sensitive medications
Despite these relaxations, the agency cautioned that drugs with a narrow therapeutic index, or those absorbed orally and sublingually, are completely excluded from this regulatory relaxation. Regarding laboratory evaluation, the agency mandated comparative dissolution tests using a production batch of at least 100,000 units or one-tenth of the actual production volume to ensure the accuracy and reliability of the results.
Expected impact on the healthcare sector locally and internationally
This regulatory update is of paramount importance on several levels. Locally, it will accelerate the availability of safe and effective generic medicines in the Saudi market, reducing the economic burden on the healthcare system and patients, and bolstering national pharmaceutical security. Regionally and internationally, this measure reinforces the Kingdom's position as a leading center for pharmaceutical regulation, as it aligns with the harmonized guidelines issued by the International Council for Harmonisation of Technical Requirements for Medicines (ICH). This alignment with advanced global standards will attract international pharmaceutical investments to the region and facilitate the import and export of medicines according to the highest quality standards.
